文献速递肿瘤 PET/CT

原发与复发乳腺癌患者CXCR4靶向PET显像

PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma.
PubMed 文献 · EJNMMI Res · 2018-09-06

这项回顾性分析纳入13例初诊乳腺癌、4例复发和1例原发灶不明腋窝淋巴结转移患者,用68Ga-Pentixafor进行CXCR4靶向PET显像并与病理预后因素及分子亚型比较。13例原发乳腺癌中9例可视觉检出(平均SUVmax 3.0),5例复发或原发不明转移灶均可检出(平均SUVmax 3.5);8例有18F-FDG PET/CT者FDG SUVmax均更高。作者结论为CXCR4 PET显像可行但肿瘤可检出性显著低于18F-FDG PET,且未见与预后因素相关,基于小样本结果似不适合作为乳腺癌通用诊断工具。

要点

  • 13例原发乳腺癌中9例68Ga-Pentixafor PET可视觉检出,平均SUVmax 3.0。
  • 5例复发或原发不明转移灶均视觉检出,平均SUVmax 3.5。
  • 8例有18F-FDG PET者FDG SUVmax均高于68Ga-Pentixafor PET。

核心结论

  • 作者结论为CXCR4靶向PET显像在原发和复发乳腺癌患者中可行,但肿瘤可检出性显著低于18F-FDG PET。
  • 作者未发现乳腺癌上述预后因素与CXCR4靶向示踪剂聚集之间存在相关性。
  • 作者基于小样本队列结果认为,CXCR4靶向PET显像似乎不适合作为乳腺癌显像的通用诊断工具。
  • 作者提出未来CXCR4显像研究应探讨该模态是否可能在更特定的应用中有用,例如治疗相关应用,尤其结合当前靶向免疫细胞与免疫检查点抑制治疗的发展。

研究设计与样本

  • 回顾性分析,纳入13例初诊乳腺癌、4例原发乳腺癌后复发和1例原发灶不明腋窝淋巴结转移患者,行68Ga-Pentixafor CXCR4靶向PET显像。
  • 测量肿瘤病灶SUVmax及肿瘤/本底比值,并与病理预后因素和分子亚型比较。
  • 18例中8例有18F-FDG PET/CT图像并作半定量比较;18例中7例与免疫组化测定的CXCR4表达进行比较。

主要发现

  • 13例原发乳腺癌中9例在68Ga-Pentixafor PET图像上可视觉检出,平均SUVmax为3.0。
  • 视觉不可检出的病灶包括2例浸润性小叶癌和2例无激素受体及HER2表达的浸润性癌非特殊型(三阴性)。
  • 复发乳腺癌和原发不明癌的转移灶在全部5例中均可视觉检出,平均SUVmax为3.5。
  • 18F-FDG PET在所有患者中显示的SUVmax均高于68Ga-Pentixafor PET。
  • 未观察到68Ga-Pentixafor PET的SUVmax与雌激素受体、孕激素受体、人表皮生长因子受体2状态、增殖指数、肿瘤分级或分子亚型等预后因素之间的相关性。

临床怎么用

  • 作者基于小样本结果认为CXCR4靶向PET显像似乎不适合作为乳腺癌显像的通用诊断工具。
  • 作者提出未来CXCR4显像研究应探讨该模态是否可能在更特定应用中有用,例如治疗相关应用。

局限性

  • 原文为回顾性分析。
  • 原文基于小样本患者队列。
  • 作者结论指出未来CXCR4显像研究应探讨该模态是否可能在更特定应用中有用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CXCR4 is a chemokine receptor frequently overexpressed in invasive breast cancer that has been shown to play a major role in signaling pathways involved in metastasis. The aim of this retrospective analysis was to assess the diagnostic performance of CXCR4-directed PET imaging in patients with breast cancer using the recently introduced CXCR4-targeted PET probe 68Ga-Pentixafor. RESULTS: Thirteen patients with first diagnosis of breast cancer, four patients with recurrent disease after primary breast cancer, and one patient with axillary lymph node metastasis of unknown primary underwent CXCR4-targeted PET imaging using 68Ga-Pentixafor. Maximum standardized uptake values (SUVmax) and tumor-to-background (T/B) ratios of tumor lesions were measured and compared with pathological prognostic factors and molecular subtypes. 18F-FDG PET/CT images were available in 8/18 cases and were compared semi-quantitatively. Comparison with CXCR4 expression determined by immunohistochemistry was performed in 7/18 patients. Nine of 13 primary breast cancers were visually detectable on 68Ga-Pentixafor PET images (mean SUVmax of 3.0). The visually undetectable lesions included both cases of invasive lobular carcinoma (ILC) and two cases of invasive carcinoma of no special type (NST) without any hormone receptor and HER2 expression (triple negative). Metastases of recurrent breast cancer and unknown primary cancer were visually detectable in all five cases, exhibiting a mean SUVmax of 3.5. 18F-FDG PET demonstrated higher SUVmax in all patients compared to 68Ga-Pentixafor PET. A correlation between SUVmax obtained from 68Ga-Pentixafor PET and prognostic factors including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) status, proliferation index, tumor grade, or molecular subtypes was not observed. CONCLUSIONS: CXCR4-directed PET imaging in patients with primary and recurrent breast cancer is feasible; however, tumor detectability is significantly lower compared to 18F-FDG PET. Moreover, we did not find any correlation between aforementioned prognostic factors of breast cancer and CXCR4-targeted tracer accumulation. Based on these results in a small patient cohort, CXCR4-targeted PET imaging does not seem to be suitable as a general diagnostic tool for imaging of breast cancer. Future CXCR4 imaging studies should investigate whether this modality might be useful in more specific applications, e.g., in therapeutic approaches especially under the view of current developments in targeted immune cell and immune checkpoint inhibitory therapy.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Vag T, Steiger K, Rossmann A, et al. PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma. EJNMMI Res. 2018. PMID: 30191351. doi:10.1186/s13550-018-0442-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。